Sera Prognostics Announces Positive Top-line Data from AVERT PRETERM TRIAL
Sera Prognostics (NASDAQ: SERA) announced positive top-line results from the AVERT PRETERM TRIAL, showcasing significant improvements in neonatal health outcomes and reduced hospitalization duration. The study involved 1,453 expectant mothers and demonstrated statistically significant reductions in severe neonatal morbidity and mortality. Both primary outcomes were met, affirming the effectiveness of the PreTRM® test-and-treat strategy. These results build upon previous studies and support ongoing trials, including the large PRIME study. The PreTRM® Test provides crucial risk assessments for spontaneous preterm birth, aiming to enhance outcomes for mothers and infants.
- Statistically significant improvement in neonatal health outcomes.
- Reduction in neonatal hospital stay length.
- Both co-primary outcomes of the trial were met.
- Strong foundation for ongoing PRIME study due to positive results.
- None.
PreTRM® test-and-treat strategy demonstrates statistically and clinically significant improvement in neonatal health outcomes and hospital length-of-stay
Both co-primary outcomes—reduction of severe neonatal morbidity or neonatal death; and decreased length of neonatal hospital stay—met their endpoints, and the improvements in outcome with a PreTRM® test-and-treat approach were statistically significant. Detailed results of the AVERT PRETERM TRIAL analysis are being prepared for publication in a peer-reviewed journal.
"The AVERT PRETERM TRIAL results demonstrate the generalizability of the PreTRM® test-and-treat strategy in achieving meaningful clinical results in widely diverse
The PreTRM® Test was broadly developed and validated for prediction of spontaneous preterm birth (sPTB) in the
About the AVERT PRETERM TRIAL
The AVERT PRETERM TRIAL evaluated the health benefit afforded to babies when pregnancies are screened with the PreTRM® Test and physicians intervened based on those results. An active arm of approximately 1,453 expectant mothers in the ChristianaCare in
About
About Preterm Birth
Preterm birth is defined as any birth before 37 weeks' gestation and is the leading cause of illness and death in newborns. The 2022 March of Dimes Report Card shows that, for the last four consecutive years, more than one in ten infants is born prematurely. Prematurity is associated with a significantly increased risk of major long-term medical complications, including learning disabilities, cerebral palsy, chronic respiratory illness, intellectual disability, seizures, and vision and hearing loss, and can generate significant costs throughout the lives of affected children. The annual health care costs to manage short- and long-term complications of prematurity in the United States were estimated to be approximately
About the PreTRM® Test
The PreTRM® Test is the only broadly validated, commercially available blood-based biomarker test that provides an early, accurate and individualized risk prediction for spontaneous preterm birth in asymptomatic singleton pregnancies. The PreTRM® Test measures and analyzes proteins in the blood that are highly predictive of preterm birth. The PreTRM® Test permits physicians to identify, during the weeks 18 through 20 of pregnancy, which women are at increased risk for preterm birth, enabling more informed, personalized clinical decisions based on each woman's individual risk. The PreTRM® Test is ordered by a medical professional.
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to preparation of detailed results of the AVERT trial for publication in a peer-reviewed journal; the AVERT findings adding to the growing body of evidence for the PreTRM test's clinical benefit to mothers and babies; the Company's view that the new AVERT results bode well for the ongoing, large multi-center PRIME study; and the company's strategic directives under the caption "About
Contact
Investor Contact
peter@capcommpartners.com
+1 (415) 389-6400
Media Contact
Glenn.silver@finnpartners.com
+1 (646) 871-8485
View original content to download multimedia:https://www.prnewswire.com/news-releases/sera-prognostics-announces-positive-top-line-data-from-avert-preterm-trial-301747486.html
SOURCE
FAQ
What are the results of the AVERT PRETERM TRIAL by Sera Prognostics?
How does the PreTRM® test impact neonatal health?
What does Sera Prognostics aim to achieve with the PreTRM® Test?
What is the significance of the AVERT PRETERM TRIAL findings for Sera Prognostics?